Although a benefit has been demonstrated from the use of bevacizumab in several tumor types, the approach of targeting only VEGF-A with bevacizumab could be responsible for resistance phenomena via activation of alternative angiogenic pathways [39,40]. This evidence concerns the gene VEGFA and neoplasm.